MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
AIxMed dedicated to transforming cancer diagnosis and monitoring, together with PathNet, a digital pathology laboratory, has formed a strategic partnership to deploy an AI-powered urine cytology workflow designed to enhance early detection of bladder cancer. The system integrates AIxMed’s AIxURO™ technology with PathNet’s digital pathology network, allowing for automated cytology slide review and classification. The collaboration aims to reduce diagnostic variability, improve turnaround times and support hospitals transitioning from manual to AI-augmented pathology.
The partnership reflects growing adoption of AI in clinical diagnostics. The AIxMed-PathNet alliance focuses specifically on cytology—a diagnostic area historically underserved by digital tools. AIxURO™ assists with the analysis of non-invasive urine cytology specimens to improve diagnostic accuracy of bladder cancer. The collaboration is aimed towards efficiency, enhancement and overall diagnostic improvement.
Posted by MedCloudInsider Editors on 11/04/20250 comments
Labviva, a leading AI-powered source-to-pay provider for life sciences, has launched its Smart Suppliers of the Future program to accelerate digital transformation in life sciences procurement. The initiative enables suppliers to digitalize their offerings and expand their reach through Labviva's supplier network. The move expands Labviva’s marketplace to over 15 million products from 18,000 manufacturers, representing 90 percent of life sciences suppliers across the U.S. and Europe.
Labviva’s network-driven approach, linking suppliers of all sizes through AI insights and real-time pricing, positions it as a leading “Amazon-style” marketplace for scientific materials. Its AI-driven insights allow no-touch forecasting, automated inventory replenishment and seamless regulatory compliance. The aim of the platform is a frictionless supply chain that accelerates scientific discovery and source-to-pay processes.
Posted by MedCloudInsider Editors on 10/27/20250 comments
Harvard Health Publishing (HHP), part of Harvard Medical School, has licensed its library of consumer health content to Microsoft to train Copilot, the company’s AI assistant. The data includes articles on disease prevention, nutrition and wellness, all reviewed by Harvard scientists and researchers. The goal is to enhance Copilot’s accuracy when responding to healthcare-related questions. Microsoft confirmed that it paid for the license.
The deal highlights a growing focus on using trusted medical sources to improve AI reliability. By leveraging peer-reviewed, clinically verified content, Microsoft aims to strengthen Copilot’s credibility in the sensitive domain of consumer health information. This license also makes content previously exclusive to HHP subscribers available to anyone who uses Microsoft Copilot.
Posted by MedCloudInsider Editors on 10/21/20250 comments
dQ&A focuses its research efforts on diabetes to produce a unique take on treatment plans. They have released a beta version of their AI Insights Platform, designed to give healthcare companies, researchers and policymakers faster access to data on the diabetes market.
Posted by MedCloudInsider Editors on 10/17/20250 comments
Microsoft has expanded Dragon Copilot, its ambient AI assistant for healthcare, to include the first commercially available version designed for nursing workflows. The update allows secure integration of partner-built AI applications and agents directly within Dragon Copilot, enabling clinicians to access tools for documentation, decision support and revenue cycle automation without leaving their workflow.
Partners include Elsevier, Wolters Kluwer, Atropos Health, Ensemble and Press Ganey, among others, offering embedded clinical references, revenue intelligence and patient engagement analytics. The expansion underscores Microsoft’s move toward an open AI ecosystem in healthcare. Dragon Copilot equips nurses with automating tasks, streamlining documentation and improving overall patient experience by assisting nurses suffering from administrative burnout. Microsoft’s extensible model signals a shift toward modular, multi-vendor AI at the point of care.
Posted by MedCloudInsider Editors on 10/17/20250 comments
Google has reported that its Gemma AI model contributed to the discovery of a new pathway that could inform cancer drug development. Using Gemma’s generative and predictive capabilities, researchers identified a novel interaction between protein signaling networks implicated in tumor growth. The findings mark one of the first demonstrations of foundation models accelerating early-stage biomedical discovery.
The breakthrough underscores AI’s expanding role in molecular biology. While in its early stages, this tool can mark the mark of powerful, experimentally validated leads for developing new combination therapies that use a combination method for more robust results. The C2S-Scale 27B model is available to the research community with a scientific preprint, the code and the actual model available online.
Posted by MedCloudInsider Editors on 10/15/20250 comments
Nobles Medical Technology 2, a provider of cardiovascular closure solutions, announced it received FDA approval to resume its NobleStitch EL clinical trial for patent foramen ovale (PFO) closure. The minimally invasive device uses a suture-only method to close the small opening between the heart’s upper chambers, offering a potential alternative to metal implants. The company paused enrollment earlier this year following requests for additional safety and performance data, which it says have now been addressed.
A Pre-Market Approval will be submitted upon completion of the study, with patient enrollments set to continue in the last quarter of 2025. The device utilizes a proprietary percutaneous suturing technique to close defects without requiring a permanent implant.
Posted by MedCloudInsider Editors on 10/07/20250 comments
ZEISS, one of the leading medical technology companies listed on the MDAX and TecDAX of the German stock exchange, expanded its ophthalmic portfolio with new surgical instruments and digital workflow capabilities aimed at improving efficiency and visualization in vitreoretinal surgery. The updates enhance integration between DORC devices and ZEISS’s digital surgery platforms, allowing real-time data capture and imaging within a connected ecosystem. The company said the expansion supports improved surgical precision and workflow standardization across operating rooms.
The announcement underscores ZEISS’s effort to lead in connected surgical ecosystems, the company said. This is an area seeing rapid digitalization. ZEISS’s combined focus on instrumentation and digital connectivity aims to differentiate it in the next phase of ophthalmic device innovations.
Posted by MedCloudInsider Editors on 10/07/20250 comments
Xenocor, a Utah-based medical device company dedicated to transforming surgical visualization, announced it has received a U.S. patent for its next-generation single-use medical borescope technology, designed to improve visualization during minimally invasive procedures. The patented system integrates a lightweight optical sensor and advanced image-processing algorithms, enabling high-resolution imaging without the need for reusable or sterilized components. The company stated that the design reduces the risk of infection and lowers maintenance costs for hospitals and surgical centers.
The patent aligns with healthcare’s shift toward disposable, infection-resistant medical devices, the company said. Xenocor’s approach, which combines affordability with real-time image quality, could appeal to smaller facilities seeking to modernize their surgical imaging without incurring significant capital investments.
Posted by MedCloudInsider Editors on 10/07/20250 comments
WaveBreak Therapeutics, a biopharmaceutical company developing a new class of therapeutics for the treatment of neurodegenerative diseases, has published new data demonstrating that its experimental compound, WTX-607, binds to and reduces alpha-synuclein aggregates in human brain tissue. The findings, shared at the International Congress of Parkinson's Disease and Movement Disorders, suggest that WTX-607 could slow or prevent neurodegeneration associated with Parkinson’s disease and Lewy body dementia. The company stated that the molecule penetrates brain tissue efficiently and has demonstrated efficacy in multiple preclinical models.
The announcement adds to a growing body of research targeting alpha-synuclein, a hallmark protein in Parkinson’s pathology. The success of the preclinical trials positions WTX-607 as a potential treatment for Parkinson's disease and Lewy body dementia.
Posted by MedCloudInsider Editors on 10/07/20250 comments
OutcomeMD has introduced the Patient Experience Data Network, the first data intelligence network powered by patient-reported outcomes (PROs). The platform aggregates de-identified data from healthcare organizations using OutcomeMD’s digital tools to measure how patients feel and function after treatment. Participating sites can benchmark outcomes, compare therapies, and access dashboards that link clinical claims and PRO data for research or value-based care initiatives. The launch aims to collect high-quality data to extract actionable insights that enable innovation and improvements in healthcare.
The Patient Experience Data Network shows patients that they are being heard and that their lived experiences are being recorded for future use, the company said.
Posted by MedCloudInsider Editors on 10/07/20250 comments
Benchling, provider of a cloud-based platform for biotechnology research and development, has launched Benchling AI, a suite of generative and predictive tools built to streamline scientific workflows across drug discovery, biomanufacturing, and genomics. The platform integrates directly with Benchling’s cloud-based data system, enabling researchers to query experiments in natural language, generate molecular annotations, and surface insights from structured and unstructured datasets. Benchling CEO Sajith Wickramasekara stated, "The goal is to put AI in the hands of every scientist and bend the speed and cost curve of making medicines." Benchling AI features agents, including the Deep Research Agent, Data Entry Agent, and Compose Agent, enabling scientists to access models in one place for optimized experiments.
The launch comes amid growing investment in AI for scientific research. Benchling claims its advantage lies in its integration with existing lab workflows, providing scientists with AI assistance within the data platforms they already use. A top 20 biopharma company has already utilized Benchling’s Deep Research Agent, reducing project length by eight months.
Posted by MedCloudInsider Editors on 10/07/20250 comments